Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/WUM865. CME/MOC/CPD/NCPD/CPE/AAPA credit will be available until June 21, 2025.

Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.